GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Novartis India Ltd

Novartis India Board Notes Sale of 17.45 Million Shares to ChrysCapital

MANAGEMENT ◆ Monitor Closely MEDIUM RISK
📅 Filed on BSE: 29 Jul 2026, 08:23 PM IST  ·  BSE ID: e072e6c1-75d2-462b-a91f-25f5084f7c12
View Original BSE Filing (PDF)
💡
In Simple Terms
Novartis India's Board acknowledged that its parent company sold over 17 million shares to ChrysCapital. The sale is now complete.
🤖 AI Summary
  • Board noted completion of Novartis AG sale of 17,450,680 equity shares to ChrysCapital.
  • Transaction, agreed in February 2026 SPA, transferred shares to WaveRise, Fund X, TIP.
  • Open Offer completion was also noted by the Board of Directors.
  • This marks a change in significant shareholding for Novartis India Ltd.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Equity Shares Sold
17,450,680
🏢 How This Affects the Company
📈
Business Impact
This transaction signifies a change in the controlling shareholding, potentially impacting the company's strategic direction under new ownership.
💰
Financial Impact
The sale of shares by Novartis AG does not directly impact Novartis India's current financial statements but may influence future capital allocation or dividend policies.
⚙️
Operational Impact
Operational impacts are not specified in this filing. Day-to-day operations are expected to continue as before, pending any new strategic directives.
⚠️
Risk Impact
A change in major shareholder can introduce new strategic risks or opportunities. The long-term implications will depend on the new promoter's plans.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this filing.
👤
Who Is Affected
Shareholders are affected by the change in the significant promoter group from Novartis AG to ChrysCapital entities.
🔍
Management Signal
Management's signal is to transparently report a completed significant shareholding transaction as per regulatory requirements.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Announcements from ChrysCapital regarding strategic plans for Novartis India.
Future quarterly results for operational performance under new ownership.
Any direct communication from new promoters on business strategy.
MEDIUM RISK Significant promoter change introduces uncertainty regarding future strategic direction and integration.
💡 Investor Takeaway
Novartis India's Board confirmed the completion of Novartis AG's sale of 17,450,680 equity shares to ChrysCapital entities. The associated open offer is also finalized.
❓ Frequently Asked Questions
What significant event did the Novartis India Board note on July 29, 2026?
The Board noted the completion of Novartis AG's sale of 17,450,680 equity shares to ChrysCapital entities.
Who were the buyers of the Novartis India shares from Novartis AG?
The shares were sold to WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners, collectively known as CC.
When was the agreement for the sale of Novartis India shares signed?
The agreement for the sale and purchase of the shares was dated February 19, 2026.
What is the total number of shares transferred in this transaction?
A total of 17,450,680 equity shares of Novartis India Limited were transferred.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.